Filing Details
- Accession Number:
- 0001179110-14-013357
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-08-28 14:35:43
- Reporting Period:
- 2014-08-26
- Filing Date:
- 2014-08-28
- Accepted Time:
- 2014-08-28 14:35:43
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
882095 | Gilead Sciences Inc | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1600041 | Rutherford Paul Carter | Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 | Evp Commercial Ops | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-08-15 | 259 | $21.94 | 32,244 | No | 5 | A | Direct | |
Common Stock | Acquisiton | 2014-08-26 | 10,000 | $19.09 | 42,244 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-08-26 | 10,000 | $106.16 | 32,244 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 5 | A | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2014-08-26 | 10,000 | $0.00 | 10,000 | $19.09 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
15,200 | 2021-01-20 | No | 4 | M | Direct |
Footnotes
- Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan..
- The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
- Sale prices reported for the transactions reported here range from $105.835 to $106.35. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.